• PDF / 210,140 Bytes
• 23 Pages / 504.57 x 720 pts Page_size
• 60 Downloads / 168 Views

DOWNLOAD

REPORT

REVIEW ARTICLE

© 2006 Adis Data Information BV. All rights reserved.

Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal Cancer State of the Art Robert B. Diasio and Jeanne Fourie Departments of Medicine and Pharmacology/Toxicology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA

Contents Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1441 1. Epidermal Growth Factor Receptor (EGFR) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1442 1.1 The EGFR Signalling Network . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1443 1.2 EGFR and Carcinogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1443 1.3 EGFR Expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1445 2. Anti-EGFR Therapeutic Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1445 2.1 Cetuximab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1445 2.1.1 Clinical Experience . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1446 2.1.2 Combination Therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1446 2.2 Additional Investigational Antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1449 3. Tyrosine Kinase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1449 3.1 Gefitinib . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1450 3.1.1 Clinical Experience . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1451 3.2 Erlotinib . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1451 3.3 Investigational Tyrosine Kinase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1452 4. Critical Issues and Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1452 4.1 EGFR Expression and Rash as Prognostic Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1452 4.2 Sequential Treatment . . . . . . . . . . . . . . . . . . . . . . .

Recommend Documents

Epidermal Growth Factor Receptor

147 88 4MB

Basic Amino Acids Within the Juxtamembrane Domain of the Epidermal Growth Factor Receptor Regulate Receptor Dimerization

178 17 2MB

Monitoring the Crosstalk Between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 with PET

168 13 419KB

Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy p

153 64 456KB

Human Epidermal Growth Factor Receptor Dimerization Analysis in Breast Cancer Diagnosis

120 60 133KB

Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery

175 14 2MB

Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kin

145 17 711KB

The Prognostic Impact of Epidermal Growth Factor Receptor (EGFR) in Patients with Acute Myeloid Leukaemia

146 66 236KB

Overcoming resistance to endocrine therapy in hormone receptor-positive human epidermal growth factor receptor 2-negativ

140 101 1MB

ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib

140 43 884KB

Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Me

165 75 544KB

Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinom

174 78 810KB